Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$456.04 USD
+6.48 (1.44%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $456.04 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
Alnylam Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ALNY 456.04 +6.48(1.44%)
Will ALNY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ALNY
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
Other News for ALNY
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Bullish Engulfing appears for ALNY after 1.44% move
Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN
ALNY: Piper Sandler Raises Price Target Amid Overweight Rating | ALNY Stock News
Barclays Raises Price Target for Alnylam Pharmaceuticals (ALNY) to $527 | ALNY Stock News